Our CEO was interviewed in this piece about the barriers and opportunities for scaling companies in the UK.
14.03.2023Our CEO was interviewed in this piece about the barriers and opportunities for scaling companies in the UK.
Our CEO was interviewed in this piece about the barriers and opportunities for scaling companies in the UK.
14.03.2023Our CEO was interviewed in this piece about the barriers and opportunities for scaling companies in the UK.
Statement from our CFO on the situation concerning SVB.
12.03.2023Featured in Technology Dispatch, bit.bio SVP of Technical Operations & Cell Manufacturing, Kathryn Golden, shares her insights int...
10.03.2023bit.bio will use Automata to automate a key aspect of its production of iPSC derived human cells
26.01.2023Our CEO gives his take on what's in store for the biotech industry in 2023 as part of this forward looking feature.
16.01.2023This series explores the fascinating interface between science and design. Episode 2 looks at synthetic biology and features our ...
23.12.2022Further products in CNS portfolio aim to address the translation gap and accelerate research and drug discovery for neurodegenerat...
23.11.2022bit.bio founder and CEO Dr Mark Kotter has 15 minutes to explain how we program biology as software to develop affordable next gen...
28.10.2022New advisors will provide important and independent guidance.
25.10.2022